Indovax was established in 1986 with a view to produce vaccines for prevalent and emerging poultry diseases in India.
This venture, initially in collaboration with Vineland Laboratories, USA, not only enabled Indovax to produce vaccines in India but also enabled it to import such vaccines as it was then not producing in India. Outbreak of Gumboro disease for the first time in 1990s was thus largely controlled by production of Georgia Strain vaccine by Indovax, and subsequent development of even more efficacious Gumboro vaccine under the brand name IV95. Indovax thus played a pivotal role in bringing under control Gumboro disease which was devastating the entire poultry population in India.
Since then, for over 30 years, Indovax has been developing and delivering safe and effective vaccines – both Live and Inactivated – to keep the poultry flocks healthy, disease-free and safe in India – and for poultry producers in several countries of Africa, South Asia, and in Nepal where Indovax vaccines are being exported in growing numbers.
Indovax is a trusted and respected name in the field of poultry vaccines. With its wide network of Distribution and Sales, Indovax vaccines are now available in virtually every part of India. And through exports in several countries of Africa and Asia. Successfully and reliably providing protection against the current poultry diseases. By special arrangement Indovax also exports vaccines in Bulk for it to be converted into vaccines locally.
Indovax WHO GMP Certified Manufacturing facility, covering 12,000 Sq. ft. across 14 acres located at Hisar in Haryana – is manned by experienced technological and scientific manpower to produce high quality, safe and efficacious vaccines.
The Company Operations are backed up by a sophisticated Research and Development Wing recognised by the Department of Science and Technology, Government of India.
Indovax remains driven by its objective of protecting the Poultry community by providing innovative and reliable vaccines solutions.